Target intelligence / Profile preview

Mutant huntingtin messenger RNA (mHTT mRNA) containing single nucleotide polymorphism rs7685686 (mHTT mRNA (rs7685686))

Target
mHTT mRNA (rs7685686)
Molecular classification
Messenger RNA, Nucleic acid
01

Overview

The target is the mutant huntingtin (HTT) messenger RNA (mRNA) transcript that specifically contains the single nucleotide polymorphism (SNP) rs7685686. This SNP is frequently found in linkage disequilibrium with the pathogenic CAG repeat expansion in the HTT gene, making it a viable target for allele-specific silencing in Huntington's disease (HD) patients (Southwell et al., 2014, Nature Communications). HD is a neurodegenerative disorder characterized by the production of toxic mutant huntingtin protein (mHTT), which leads to neuronal death, particularly in the striatum (Ross & Tabrizi, 2011, Lancet Neurology). By targeting the mRNA sequence containing rs7685686, therapeutic agents such as antisense oligonucleotides (ASOs) can selectively induce the degradation of the mutant transcript while sparing the wild-type HTT mRNA (Skotte et al., 2014, PLOS ONE). This approach is designed to maintain the essential biological functions of the wild-type protein, which is involved in axonal transport and neuroprotection (Zuccato et al., 2010, Physiological Reviews). Clinical development of such allele-specific therapies requires patient stratification based on the presence of the rs7685686 SNP to ensure target engagement (Kay et al., 2014, BMC Medical Genetics). The use of rs7685686 as a molecular handle allows for the treatment of a significant subpopulation of HD patients who carry this specific genetic signature.

Other names
Mutant HTT mRNAmHTT mRNA (rs7685686)Huntingtin mRNA containing rs7685686SNP1-containing huntingtin transcript
02

Mechanism of action

Allele-specific knockdown of mutant huntingtin mRNA via RNase H-mediated degradation or RNA interference-mediated cleavage

03

Biological functions

Protein translationGenetic information transfer
04

Disease associations

Huntington's disease
05

Safety considerations

Off-target silencing of wild-type huntingtin mRNAPotential for inflammatory or immune responses to synthetic oligonucleotidesRisks associated with chronic intrathecal administration
06

Interacting drugs

Allele-specific antisense oligonucleotides

1 more in the full profile.

07

Biomarkers

rs7685686 genotypeMutant huntingtin protein (mHTT) levels in cerebrospinal fluidNeurofilament light chain (NfL) levels

Beyond the preview

Go deeper on Mutant huntingtin messenger RNA (mHTT mRNA) containing single nucleotide polymorphism rs7685686 (mHTT mRNA (rs7685686)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mutant huntingtin messenger RNA (mHTT mRNA) containing single nucleotide polymorphism rs7685686 (mHTT mRNA (rs7685686)).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call